Phase 4 Type 2 Diabetes Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People with a body mass index (a measure of body weight relative to height) of 23 or above (or 22 or above for people of Asian background), but below 45.
- People whose blood sugar level (measured by a test called HbA1c, which reflects average blood sugar over a few months) is between 5.7% and 8.0%, and who are not currently taking any medications to lower blood sugar.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have had a heart attack, stroke, or other serious heart or blood vessel event in the past 6 months.
- People with an active cancer, kidney disease, liver disease, pregnancy or breastfeeding, a chronic inflammatory condition, an eating disorder, or who have previously had weight-loss (bariatric) surgery.
- People with a history of a serious inflammation of the pancreas (acute pancreatitis).
- People with a personal or family history of a specific type of thyroid cancer called medullary thyroid cancer.
- People currently taking medications that lower blood sugar, raise blood sugar, or promote weight loss (though a period of stopping these medications may be allowed if a primary doctor approves).
- People who drink heavily on a regular basis.
- People whose blood test results show low red blood cell levels, elevated kidney markers, or elevated liver enzyme levels beyond certain thresholds (confirm with trial site for exact values).
- People who do more than 2 hours of physical activity per day.
- People who are unable to attend in-person metabolic testing at Stanford's Clinical and Translational Research Unit (CTRU).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tracey McLaughlin, MD, Stanford University
Phone: 7144884516
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in HbA1c
Can't join this trial?
Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.